



## EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

May 26, 2021

WATERTOWN, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Jefferies Healthcare Conference on June 2, 2021 at 9:30 a.m. ET.

A live webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at [www.eyepointpharma.com](http://www.eyepointpharma.com). The replay will be available for 90 days after the event.

**About EyePoint Pharmaceuticals, Inc.** (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert<sup>®</sup> technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ<sup>®</sup>, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU<sup>®</sup>, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit [www.eyepointpharma.com](http://www.eyepointpharma.com) and connect on Twitter and LinkedIn.

### Investors:

Christina Tartaglia  
Stern IR  
Direct: 212-698-8700  
[christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)

### Media Contact

Green Room Public Relations  
Caren Begun  
Green Room Communications  
Direct: (201) 396-8551  
[caren@greenroompr.com](mailto:caren@greenroompr.com)



Source: EyePoint Pharmaceuticals, Inc.